CME

Faculty: Javier Cortes, MD, PhD This online educational activity examines the evolving role of TROP2-directed antibody-drug conjugates (ADCs) in the frontline management of metastatic triple-negative breast cancer (TNBC). Through expert-led reviews and case-based discussions, the activity compares pivotal clinical trial data for emerging ADCs, with a focus on patients who are not candidates for im...

Host: Alexandria May, PharmD, BCPS Guest: Helena A. Yu, MD Guest: Vicki Sherry, DNP, ANP-BC, AOCNP Over the past two decades, advances in disease biology and precision medicine have transformed the diagnosis and treatment of non–small cell lung cancer (NSCLC). Improved understanding of NSCLC molecular drivers has led to the development of targeted therapies and immunotherapies that have enhanced d...

Faculty: Karen E. Anderson, MD Faculty: Hubert H. Fernandez, MD This Podcast Plus discussion reviews how treatment for tardive dyskinesia can be individualized based on patient-specific goals and pharmacologic considerations. The program examines clinically relevant differences among VMAT2 inhibitors, including factors such as speed of response, durability, tolerability, and regimen simplicity. It...

Faculty: Brendon Neuen, MBBS, PhD Faculty: Katherine Tuttle, MD A growing body of evidence presented at ERA 2026 is reshaping the conversation around chronic kidney disease management, regardless of diabetes status. In this expert interview, Dr. Katherine Tuttle and Dr. Brendon Neuen examine emerging data on nonsteroidal mineralocorticoid receptor antagonists and discuss how recent findings may ex...

Faculty: Roger McIntyre, MD Faculty: Emmanuel Mignot, MD, PhD Sleep and psychiatric disorders are often managed separately in clinical practice, leaving key biological mechanisms unaddressed and contributing to recurrent cycles of relapse. Overlapping factors, including orexin-driven arousal mechanisms, REM sleep abnormalities, limited use of validated screening tools, and incomplete differential...

Host: Jörg Latus, MD Faculty: Sayna Norouzi, MD Focal segmental glomerulosclerosis (FSGS) remains a challenging disease, with many patients progressing to kidney failure and experiencing substantial effects on quality of life. As the treatment landscape evolves, clinicians must understand how emerging therapies may influence disease management and patient outcomes. Join Drs. Jörg Latus and Sayna N...

Faculty: Jose Rubio, MD Although dopamine D₂ receptor antagonists have long been the standard treatment for schizophrenia, many patients experience inadequate symptom control or adverse effects that affect adherence. Emerging evidence supports a role for muscarinic M₁/M₄ receptor dysfunction in schizophrenia, leading to the development of therapies with mechanisms distinct from dopamine blockade....

Guest: Emma Guttman, MD, PhD Emma Guttman, MD, PhD, discusses the disconnect that sometimes exists in atopic dermatitis between clinical trials and real-world situations.

Faculty: Susana Campos, MD, MPH Faculty: Robert Coleman, MD, FACOG Faculty: Debra Richardson, MD This chapterized online educational activity is designed to translate biomarker-driven evidence into practical decision-making across the ovarian cancer continuum. Through expert discussion, participants will apply biomarker insights to guide treatment strategies in both frontline maintenance and plati...

Faculty: Prem S. Subramanian, MD, PhD Faculty: Kimberly Cockerham, MD Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. D...

Faculty: Andrea Lora Kossler, MD, FACS Faculty: Kimberly Cockerham, MD Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care....

Faculty: Prem S. Subramanian, MD, PhD Faculty: Andrea Lora Kossler, MD, FACS Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered...

Faculty: Prem S. Subramanian, MD, PhD Faculty: Kimberly Cockerham, MD Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. D...

Faculty: Prem S. Subramanian, MD, PhD Faculty: Andrea Lora Kossler, MD, FACS Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered...

Faculty: Prem S. Subramanian, MD, PhD Faculty: Kimberly Cockerham, MD Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care. D...

Faculty: Prem S. Subramanian, MD, PhD Faculty: Andrea Lora Kossler, MD, FACS Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered...

Faculty: Andrea Lora Kossler, MD, FACS Faculty: Kimberly Cockerham, MD Join our experts as they explore why clinical activity scores (CAS) alone often fail to capture the full impact of thyroid eye disease (TED) severity and what tools can help align treatment with patients’ true disease burden. See how emerging TED therapies and the latest clinical trial data are reshaping patient-centered care....

Faculty: Neeraj Agarwal, MD, FASCO Faculty: Rana McKay, MD This podcast explores the evolving role of molecular profiling and biomarker testing in metastatic castration-sensitive prostate cancer (mCSPC). Drs. Neeraj Agarwal and Rana McKay discuss the clinical significance of PTEN loss and other genomic alterations, their prognostic implications, and how they may inform treatment selection. The con...

Faculty: Neeraj Agarwal, MD, FASCO Faculty: Rana McKay, MD In this podcast, Drs. Rana McKay and Neeraj Agarwal discuss risk stratification in localized and nonmetastatic castration-sensitive prostate cancer (CSPC), highlighting the clinical and imaging factors used to identify patients at increased risk of recurrence and disease progression. The faculty examine the evolving role of treatment inten...

Faculty: Jorge Plutzky, MD Faculty: Bradley Eilerman, MD, MHI With our current understanding of how prevalent hypercortisolism is in patients with difficult-to-manage cardiometabolic disease, the focus shifts to what might clinicians do differently in practice? Which patients should healthcare providers screen, and what straightforward testing methods can be used to detect and confirm hypercortiso...

Faculty: Alireza Atri, MD, PhD Faculty: Raymond Scott Turner, MD, PhD Faculty: Dani Cabral, MD In this activity, Dr. Alireza Atri and Dr. Scott Turner discuss the evolving role of subcutaneous anti-amyloid monoclonal antibody therapy in early Alzheimer disease. The conversation compares intravenous and subcutaneous administration and focuses on maintenance dosing after 18 months of IV therapy, pra...

Faculty: Muthiah Vaduganathan, MD, MPH Faculty: Koichiro Kinugawa, MD Faculty: Michael Böhm, MD In this panel discussion from the ESC Heart Failure Congress 2026, Drs. Muthu Vaduganathan, Michael Böhm, and Koichiro Kinugawa discuss the role of nonsteroidal MRAs in patients with HFmrEF and HFpEF. Using a clinical case, the faculty review evolving recommendations supporting finerenone as part of gu...

Faculty: Sayna Norouzi, MD In this Patient-Clinician Connection, Dr. Sayna Norouzi discusses shared decision-making approaches for adult patients with C3 glomerulonephritis (C3GN) receiving complement-targeted therapies. Through a clinical patient vignette, Dr. Norouzi demonstrates patient-centered communication techniques for discussing mechanisms, treatment considerations, and long-term kidney p...

Faculty: Scott T. Tagawa, MD, MS Faculty: Mary-Ellen Taplin, MD This activity explores current approaches to treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC), including androgen deprivation therapy (ADT), androgen receptor pathway inhibitors (ARPIs), chemotherapy, and emerging targeted therapies. Drs. Scott Tagawa and Mary-Ellen Taplin discuss how disease volume, m...

Faculty: Susan L Samson, MD, PhD, FRCPC, FACE Faculty: Lawrence Blonde, MD, FACP, FACE Updated diabetes guidelines now recognize a new “other” category of diabetes linked to excess cortisol. This classification reflects emerging prevalence data showing that hypercortisolism may play a much larger role in diabetes development than previously understood. Let’s explore what these new guidelines mean...